Senvest Management LLC lifted its position in shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 458.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 314,629 shares of the biotechnology company’s stock after purchasing an additional 258,329 shares during the quarter. Senvest Management LLC owned about 1.38% of Concert Pharmaceuticals worth $4,641,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CNCE. TIAA CREF Investment Management LLC boosted its position in shares of Concert Pharmaceuticals by 18.0% during the first quarter. TIAA CREF Investment Management LLC now owns 125,183 shares of the biotechnology company’s stock valued at $2,136,000 after purchasing an additional 19,078 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Concert Pharmaceuticals by 6.1% during the first quarter. Vanguard Group Inc. now owns 681,712 shares of the biotechnology company’s stock valued at $11,630,000 after purchasing an additional 38,892 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Concert Pharmaceuticals by 0.6% during the first quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock valued at $2,435,000 after purchasing an additional 838 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Concert Pharmaceuticals by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 32,349 shares of the biotechnology company’s stock valued at $552,000 after purchasing an additional 19,046 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Concert Pharmaceuticals by 47.9% during the second quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock valued at $449,000 after purchasing an additional 10,400 shares in the last quarter. Institutional investors own 65.34% of the company’s stock.

In other Concert Pharmaceuticals news, insider Value Fund L. P. Biotechnology purchased 331,916 shares of the firm’s stock in a transaction dated Thursday, October 19th. The stock was purchased at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ryan Lynch sold 3,500 shares of the business’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $14.51, for a total value of $50,785.00. Following the completion of the transaction, the insider now owns 9,500 shares of the company’s stock, valued at approximately $137,845. The disclosure for this sale can be found here. 10.10% of the stock is currently owned by insiders.

Concert Pharmaceuticals Inc (NASDAQ:CNCE) opened at $23.85 on Monday. Concert Pharmaceuticals Inc has a one year low of $7.11 and a one year high of $24.04.

A number of research analysts have issued reports on CNCE shares. Zacks Investment Research cut Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Concert Pharmaceuticals in a research note on Monday, September 18th. ValuEngine upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Mizuho started coverage on Concert Pharmaceuticals in a research note on Thursday, October 26th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $30.00 price objective on shares of Concert Pharmaceuticals in a research note on Sunday, October 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Concert Pharmaceuticals presently has an average rating of “Hold” and an average price target of $23.00.

TRADEMARK VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/12/04/senvest-management-llc-grows-position-in-concert-pharmaceuticals-inc-cnce.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Stock Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.